SURMOUNT
The study will assess the effect of tirzepatide at the maximum tolerated dose (10 mg or 15 mg QW) compared with placebo in people living with obesity
- Stage
- followup
- Medicine
- Tirzepatide
- Population
- ASCVD
- Phase
- III
- First Patient In
- 31 January 2023
- Last Patient In
- 5 February 2024
- Last Patient Last Visit
- 30 June 2029
National Lead
dr. A.F.M. Kuijper
Cardioloog
Study Director
drs. M.J. Asselman
Cardioloog
Office Contact
